Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
AGNC Investment Corp.
AGNC·Real Estate
F Avoid
Current$8.78
Oct 22, 2026

AGNC offers substantial monthly dividend income and potential upside from tighter mortgage spreads, but leveraged book-value losses, narrow payout coverage, and a premium to tangible equity undermine its current risk-reward profile.

Score
42
Relay Therapeutics, Inc.
RLAY·Healthcare
F Avoid
Current$18.60
Nov 7, 2026

Relay Therapeutics has a differentiated precision-oncology pipeline and substantial clinical upside, but its precommercial economics, dilution and demanding valuation make future shareholder returns highly dependent on successful trials.

Score
41
Hut 8 Corp.
HUT·Financials
F Avoid
Current$52.65
Nov 7, 2026

Hut 8 offers substantial long-term AI data center growth potential through contracted power infrastructure, but negative free cash flow, complex project financing, and demanding execution requirements weaken the investment case.

Score
41
Cipher Digital Inc.
CIFR·Technology
F Avoid
Current$6.50
Nov 5, 2026

Cipher Digital has significant long-term AI data center growth potential through contracted hyperscale infrastructure, but negative cash flow, heavy project financing and shareholder dilution currently undermine its investment appeal.

Score
39
Uranium Energy Corp.
UEC·Energy
F Avoid
Current$9.36
Oct 2, 2026

Uranium Energy offers scarce U.S. uranium assets and rapidly accelerating production, but extreme revenue multiples, negative free cash flow and persistent dilution require far more execution than current fundamentals support.

Score
39
SELLAS Life Sciences Group, Inc.
SLS·Healthcare
F Avoid
Current$15.46
Aug 25, 2026

SELLAS is a high-risk oncology binary bet on a potentially curative AML vaccine and a promising CDK9 inhibitor, but heavy recent dilution and a $3.12 billion valuation priced for perfection argue for avoiding the downside risk.

Score
39
Dianthus Therapeutics, Inc.
DNTH·Healthcare
F Avoid
Current$90.00
Nov 10, 2026

Dianthus Therapeutics offers meaningful upside through differentiated autoimmune therapies and a well-funded late-stage pipeline, but its high valuation, unproven commercial model, and substantial dilution create an unfavorable risk-reward profile.

Score
38
GRAIL, Inc.
GRAL·Healthcare
F Avoid
Current$121.44
Nov 7, 2026

GRAIL offers substantial long-term growth potential through Galleri's multi-cancer screening technology and pending FDA approval, but weak operating economics, persistent cash burn, dilution, and demanding valuation undermine its current risk-reward profile.

Score
38
Aurora Innovation, Inc.
Current$4.36
Oct 31, 2026

Aurora could become a leading autonomous trucking platform as driverless fleets scale, but its extreme valuation relative to revenue, persistent cash burn, and shareholder dilution make execution risk substantial.

Score
38
Erasca, Inc.
ERAS·Healthcare
F Avoid
Current$15.66
Nov 14, 2026

Erasca's promising pan-RAS oncology pipeline and substantial cash reserves create significant clinical upside, but its unproven commercialization, elevated valuation, and shareholder dilution make the investment highly speculative.

Score
37
MARA Holdings, Inc.
MARA·Financials
F Avoid
Current$7.66
Nov 12, 2026

MARA's extensive power portfolio and emerging AI infrastructure contracts offer long-term growth optionality, but declining mining revenue, persistent cash burn, and uncertain project economics undermine its investment appeal.

Score
37
Spyre Therapeutics, Inc.
SYRE·Healthcare
F Avoid
Current$109.00
Nov 10, 2026

Spyre Therapeutics offers substantial long-term potential through differentiated immunology combinations and strong liquidity, but unproven commercial economics, dilution, and demanding clinical expectations create significant investment risk.

Score
37